Phase 1b/2a Study Combining LY2157299 With Standard Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma.

Trial Profile

Phase 1b/2a Study Combining LY2157299 With Standard Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Galunisertib (Primary) ; Temozolomide
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
  • Focus Adverse reactions; Biomarker; Proof of concept; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 03 Feb 2017 This trial was completed in Germany (End date: 23 Nov 2016), according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top